← Evidence map

ArticleCNS drugs2025

Comment on "A Multicenter, Open-Label Study to Evaluate the Long-Term Safety and Efficacy of Adjunctive Brexpiprazole 2 mg Daily in Japanese Patients with Major Depressive Disorder"'.

Chenxi Wang et al.PubMed ↗Publisher ↗

No numbers read from the abstract.

Not cited yet

Comment on "A Multicenter, Open-Label Study to Evaluate the Long-Term Safety and Efficacy of Adjunctive Brexpiprazole 2 mg Daily in Japanese Patients with Major Depressive Disorder"'. | OpenQuestion